Head to head
Thymosin Alpha-1 vs LL-37
Two compounds, one grading system.
On human evidence, Thymosin Alpha-1 currently leads: well researched versus emerging.
01
At a glance
Thymosin Alpha-1Well researched
Immune modulator approved in several countries for hepatitis and adjuvant use.
1,442publications
55RCTs
LL-37Emerging
Human antimicrobial peptide. Important biology, limited therapeutic human data.
3,768publications
40RCTs
02
Side by side
| Attribute | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Goal | Immunity | Immunity |
| Evidence | Well researched | Emerging |
| Publications | 1,442 | 3,768 |
| Randomised trials | 55 | 40 |
| Sport (WADA) | — | S0 — prohibited |
| US compounding | — | — |
03
Claims vs data
Thymosin Alpha-1 — claims vs data
| Approved in several countries for chronic hepatitis B | supported |
| Modulates T-cell function | supported |
| Boosts immunity in healthy people | weak evidence |
LL-37 — claims vs data
| Kills microbes in laboratory models | preclinical only |
| A core component of human innate immunity | supported |
| Treats chronic infections when injected | weak evidence |